x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

33:48

184. ESMO Awards - Episode 4

Oncology for the Inquisitive Mind ·

2025/12/13

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex

en

28:33

183. ESMO Awards - Episode 3

Oncology for the Inquisitive Mind ·

2025/12/05

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.Studies:DeLLphi-303SOHO-01ALBATROSPAULIENDREAM3ROptiTROP-Lung04For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats:

en

42:16

182. ESMO Awards - Episode 2

Oncology for the Inquisitive Mind ·

2025/11/26

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial

en

34:06

182. ESMO Awards, Episode 1

Oncology for the Inquisitive Mind ·

2025/11/15

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.For more episodes, resources and blog posts,

en

22:20

181. Back to Basics - Limited Stage Small Cell Lung...

Oncology for the Inquisitive Mind ·

2025/10/18

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the management of limited-stage small cell lung cancer, which while accounting for a minority of cases, is no less interesting and potentially confusing. Studies discussed in this episode:PCI Meta AnalysisADRIATICFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease

en

18:12

180. Metastatic NSCLC feat. KRAS and MET mutations

Oncology for the Inquisitive Mind ·

2025/10/12

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity.Studies discussed in this episode:INSIGHT-2KRYSTAL-12For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or

en

24:44

179. Back to Basics: Metastatic NSCLC feat. EGFR and...

Oncology for the Inquisitive Mind ·

2025/10/05

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? You'll just have to listen and find out.Studies discussed in this episode:MARIPOSACROWNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look

en

19:22

178. Back to Basics - Metastatic Non Small Cell Lung...

Oncology for the Inquisitive Mind ·

2025/09/27

Advanced or Metastatic Non Small Cell Lung Cancer (mNSCLCa), is one of the most common causes of death worldwide. This week, Michael provides an excellent background on this type of cancer, and Josh provides an eloquently short introduction (for once). These trials look specifically at lung cancers without mutations, thus relying on immunotherapy and chemotherapy.As a side note, can you believe Keynote189 is over 7 years old! How time flies!Studies discussed in this episode:Keynote 189Checkmate

en

24:01

177. Early NSCLC

Oncology for the Inquisitive Mind ·

2025/09/13

To Josh's immense displeasure, our series on genitourinary cancer is done. For now, at least. In this episode, Michael and Josh step into the heavy shadow of non-small cell lung cancer, the most common cause of cancer death in Australia. However, there is hope and new developments in the early-disease space that could significantly improve outcomes. Studies discussed in this episodeCheckmate 816neoADAURAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on

en

18:32

176. Germ cell tumours (part 2)

Oncology for the Inquisitive Mind ·

2025/09/06

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough!Studies discussed in this episodeBEP - Williams et al (1987)TIP - Gleeson et al (20224)For more episodes, resources and blog posts, visit

en

18:34

175. Germ Cell Tumours (part 1)

Oncology for the Inquisitive Mind ·

2025/08/30

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary centre to treat adequately. Or, you could just listen to Oncology for the Inquisitive Mind and be a pro in no time!Studies discussed in this episodeEORTC-30982de Wit et al (2001)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter

en

20:05

174. Non clear-cell RCC

Oncology for the Inquisitive Mind ·

2025/08/24

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of siblings to the much better established clear cell RCC. Treatment is on very similar patterns, so their studies today involve a lot of immunotherapy with a smattering of tyrosine kinase inhibitors.Studies discussed in this episodeKEYNOTE-B61Checkmate 920For more episodes, resources and blog

en

19:08

173. NECTA (New South Wales Early Phase Clinical...

Oncology for the Inquisitive Mind ·

2025/08/17

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Early Phase Clinical Trials Alliance (NECTA) plays a key role in speeding up the translation of cutting-edge medical research into real-world treatments, providing vital benefits to patients and the broader healthcare system. By uniting a network of leading hospitals, research institutions, and clinical

en

19:25

172. Back to Basics - Advanced ccRCC

Oncology for the Inquisitive Mind ·

2025/08/09

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a predilection for the CNS and significant bleeding risk has become significantly less so. In this episode, Josh and Michael explore the studies that have made it happen.Studies discussed in this episodeCLEARCheckmate 214Checkmate 9ERFor more episodes, resources and blog posts, visit

en

14:41

171. Back to Basics - Early Clear Cell Renal Cell...

Oncology for the Inquisitive Mind ·

2025/08/02

Continuing on their Back to Basics GU extravaganza, Josh and Michael progress to the subject of kidney cancer, and bring you the answer to a question long unanswered: is there any benefit of adjuvant therapy in resected clear cell renal cell cancer. For a long time, this space produced negative study after negative study, until, as is so often the case, immunotherapy swooped in to save the day.Studies discussed in this episodeS-TRACKEYNOTE-564For more episodes, resources and blog posts, visit

en

18:26

170. Back to Basics - Adjuvant Urothelial Cancer

Oncology for the Inquisitive Mind ·

2025/07/26

Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial cancer, focussing on the sometimes contradictory data of adjuvant immunotherapy. This is an emerging area of treatment that you will not want to miss!Studies discussed in this episodeAMBASSADORCheckmate 274IMvigor010For more episodes, resources and blog posts, visit

en

33:40

169. ASCO 2025 - Colorectal Cancer with Prof Jeanne Tie

Oncology for the Inquisitive Mind ·

2025/07/05

In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the practice changing BREAKWATER study, combining chemotherapy with encorafenib and cetuximab, they also discuss the plenary study ATOMIC III, the CHALLENGE study examining structured exercise programs for patients with resected cancer, as well as the emerging role of ctDNA in colon and anal

en

30:31

168. ASCO 2025 - Early Breast Cancer with Dr. Belinda...

Oncology for the Inquisitive Mind ·

2025/07/03

In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication to assist with vasomotor symptoms from endocrine therapy, the ongoing follow up from the pivotal SOFT/TEXT study, an escalation strategy for abemaciclib and a de-escalation strategy for neoadjuvant chemotherapy in HER2 positive breast cancer.Studies discussed in this episodeOASISSOFT/TEXT, 15 year

en

31:22

167. ASCO 2025 - Upper GI and Hepatobiliary Cancer...

Oncology for the Inquisitive Mind ·

2025/06/30

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy in pancreatic cancer, and a small study examining a perioperative approach to resectable biliary tract

en

38:44

166. ASCO 2025 - Gynecological Oncology with Dr....

Oncology for the Inquisitive Mind ·

2025/06/28

Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST trial on ovarian cancer surgery timing, the Rosella trial for platinum-resistant ovarian cancer, the FIRST study on immunotherapy in advanced ovarian cancer, and the update on the Keynote A18 trial for cervical cancer. The discussion emphasizes the importance of these studies in shaping future treatment

en

202 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown